Meneldor
Overview
Meneldor is a venture capital firm founded in 2016. It invests in early-stage biotechnology and pharmaceutical companies that (re)develop (New) Biological or Chemical Molecular Entities, that have outstanding technology with strong IP, address significant unmet medical needs and commercially attractive markets. The firm thoroughly studies the science behind her potential portfolio companies and assesses key aspects such as IP, medical need, addressable markets, competition, risk, management, financial needs, and valuation.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Hemispherian AS | Nov 2022 | Series A | Lead |
| Tagworks Pharmaceuticals | Jun 2023 | Series A | Co-investor |
| LightOx Ltd | Oct 2021 | Seed | Co-investor |
| TIBEAY Biosciences | Apr 2026 | VC Round | Co-investor |
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Meneldor based?
Meneldor is headquartered in Druten, Gelderland, Netherlands.
When was Meneldor founded?
Meneldor was founded in 2016.
How many portfolio companies does Meneldor have?
Meneldor has 5 portfolio companies in Caplight's dataset.
What are some companies in Meneldor's portfolio?
Portfolio companies visible on Caplight include Hemispherian AS, Tagworks Pharmaceuticals, LightOx Ltd, TIBEAY Biosciences.
What was Meneldor's most recent investment shown here?
Meneldor's most recent investment in this portfolio sample was in TIBEAY Biosciences in 2026.
What sectors does Meneldor focus on?
Meneldor focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences.
What company stages does Meneldor focus on?
Meneldor typically invests at the Early stage.
What is Meneldor's AUM?
Meneldor's assets under management are estimated between $0.0 and $50.0M.